Amgen Inc (AMGN)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Key Insights
Share Price
$316.09Market Cap
$169.56 BillionTotal Outstanding Shares
536.44 Million SharesTotal Employees
26,700Dividend
$2.25 Per Share QuarterlyIPO Date
June 17, 1983SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.amgen.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-27.79 Billion |
Net Cash Flow From Financing Activities, Continuing | $-3.61 Billion |
Net Cash Flow From Financing Activities | $-3.61 Billion |
Net Cash Flow From Investing Activities, Continuing | $-27.79 Billion |
Net Cash Flow From Operating Activities, Continuing | $6.45 Billion |
Net Cash Flow From Operating Activities | $6.45 Billion |
Net Cash Flow, Continuing | $-24.95 Billion |
Net Cash Flow | $-24.95 Billion |
Income Statement
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Gross Profit | $19.58 Billion |
Diluted Earnings Per Share | $5.82 |
Nonoperating Income/Loss | $545.00 Million |
Basic Average Shares | $1.61 Billion |
Diluted Average Shares | $1.61 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income/Loss From Continuing Operations After Tax | $3.13 Billion |
Income Tax Expense/Benefit | $395.00 Million |
Revenues | $30.93 Billion |
Selling, General, and Administrative Expenses | $7.22 Billion |
Net Income/Loss | $3.13 Billion |
Costs And Expenses | $24.74 Billion |
Operating Income/Loss | $6.19 Billion |
Basic Earnings Per Share | $5.85 |
Operating Expenses | $13.39 Billion |
Cost Of Revenue | $11.35 Billion |
Net Income/Loss Attributable To Parent | $3.13 Billion |
Other Operating Expenses | $6.17 Billion |
Benefits Costs and Expenses | $27.41 Billion |
Income/Loss From Continuing Operations Before Tax | $3.52 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $3.13 Billion |
Income/Loss From Equity Method Investments | $25.00 Million |
Income/Loss Before Equity Method Investments | $3.52 Billion |
Balance Sheet
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Assets | $90.91 Billion |
Liabilities | $84.98 Billion |
Inventory | $8.00 Billion |
Intangible Assets | $30.17 Billion |
Equity Attributable To Parent | $5.92 Billion |
Other Current Liabilities | $19.25 Billion |
Fixed Assets | $6.10 Billion |
Equity | $5.92 Billion |
Other Current Assets | $19.21 Billion |
Other Non-current Liabilities | $820.00 Million |
Current Liabilities | $21.52 Billion |
Current Assets | $27.21 Billion |
Liabilities And Equity | $90.91 Billion |
Noncurrent Assets | $63.70 Billion |
Accounts Payable | $2.27 Billion |
Other Non-current Assets | $27.43 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Noncurrent Liabilities | $63.47 Billion |
Long-term Debt | $62.65 Billion |
Historical Dividends
Current dividend: $2.25 Per Share Quarterly
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
Aug 2, 2024 | Sep 6, 2024 | Aug 16, 2024 | $2.25 | Quarterly |
Mar 6, 2024 | Jun 7, 2024 | May 17, 2024 | $2.25 | Quarterly |
Dec 12, 2023 | Mar 7, 2024 | Feb 16, 2024 | $2.25 | Quarterly |
Oct 24, 2023 | Dec 8, 2023 | Nov 17, 2023 | $2.13 | Quarterly |
Aug 1, 2023 | Sep 8, 2023 | Aug 18, 2023 | $2.13 | Quarterly |
Mar 7, 2023 | Jun 8, 2023 | May 18, 2023 | $2.13 | Quarterly |
Dec 12, 2022 | Mar 8, 2023 | Feb 15, 2023 | $2.13 | Quarterly |
Oct 28, 2022 | Dec 8, 2022 | Nov 17, 2022 | $1.94 | Quarterly |
Aug 3, 2022 | Sep 8, 2022 | Aug 18, 2022 | $1.94 | Quarterly |
Mar 2, 2022 | Jun 8, 2022 | May 17, 2022 | $1.94 | Quarterly |
Dec 3, 2021 | Mar 8, 2022 | Feb 15, 2022 | $1.94 | Quarterly |
Oct 21, 2021 | Dec 8, 2021 | Nov 16, 2021 | $1.76 | Quarterly |
Jul 30, 2021 | Sep 8, 2021 | Aug 17, 2021 | $1.76 | Quarterly |
Mar 3, 2021 | Jun 8, 2021 | May 17, 2021 | $1.76 | Quarterly |
Dec 16, 2020 | Mar 8, 2021 | Feb 15, 2021 | $1.76 | Quarterly |
Oct 21, 2020 | Dec 8, 2020 | Nov 16, 2020 | $1.6 | Quarterly |
Jul 23, 2020 | Sep 8, 2020 | Aug 17, 2020 | $1.6 | Quarterly |
Mar 4, 2020 | Jun 8, 2020 | May 18, 2020 | $1.6 | Quarterly |
Dec 11, 2019 | Mar 6, 2020 | Feb 14, 2020 | $1.6 | Quarterly |
Oct 22, 2019 | Dec 6, 2019 | Nov 15, 2019 | $1.45 | Quarterly |
Aug 2, 2019 | Sep 6, 2019 | Aug 15, 2019 | $1.45 | Quarterly |
Mar 7, 2019 | Jun 7, 2019 | May 17, 2019 | $1.45 | Quarterly |
Dec 7, 2018 | Mar 8, 2019 | Feb 15, 2019 | $1.45 | Quarterly |
Oct 23, 2018 | Dec 7, 2018 | Nov 16, 2018 | $1.32 | Quarterly |
Jul 31, 2018 | Sep 7, 2018 | Aug 17, 2018 | $1.32 | Quarterly |
Mar 7, 2018 | Jun 8, 2018 | May 17, 2018 | $1.32 | Quarterly |
Dec 12, 2017 | Mar 8, 2018 | Feb 15, 2018 | $1.32 | Quarterly |
Oct 24, 2017 | Dec 8, 2017 | Nov 17, 2017 | $1.15 | Quarterly |
Jul 28, 2017 | Sep 8, 2017 | Aug 17, 2017 | $1.15 | Quarterly |
Mar 7, 2017 | Jun 8, 2017 | May 17, 2017 | $1.15 | Quarterly |
Dec 20, 2016 | Mar 8, 2017 | Feb 15, 2017 | $1.15 | Quarterly |
Oct 14, 2016 | Dec 8, 2016 | Nov 16, 2016 | $1 | Quarterly |
Jul 22, 2016 | Sep 8, 2016 | Aug 17, 2016 | $1 | Quarterly |
Mar 2, 2016 | Jun 8, 2016 | May 17, 2016 | $1 | Quarterly |
Dec 15, 2015 | Mar 8, 2016 | Feb 16, 2016 | $1 | Quarterly |
Oct 14, 2015 | Dec 7, 2015 | Nov 16, 2015 | $0.79 | Quarterly |
Jul 28, 2015 | Sep 8, 2015 | Aug 17, 2015 | $0.79 | Quarterly |
Mar 4, 2015 | Jun 5, 2015 | May 14, 2015 | $0.79 | Quarterly |
Dec 17, 2014 | Mar 6, 2015 | Feb 12, 2015 | $0.79 | Quarterly |
Oct 17, 2014 | Dec 5, 2014 | Nov 13, 2014 | $0.61 | Quarterly |
Jul 25, 2014 | Sep 5, 2014 | Aug 14, 2014 | $0.61 | Quarterly |
Mar 5, 2014 | Jun 6, 2014 | May 15, 2014 | $0.61 | Quarterly |
Dec 13, 2013 | Mar 7, 2014 | Feb 13, 2014 | $0.61 | Quarterly |
Jul 26, 2013 | Sep 6, 2013 | Aug 16, 2013 | $0.47 | Quarterly |
Mar 6, 2013 | Jun 7, 2013 | May 16, 2013 | $0.47 | Quarterly |
Dec 13, 2012 | Mar 7, 2013 | Feb 13, 2013 | $0.47 | Quarterly |
Oct 10, 2012 | Dec 7, 2012 | Nov 15, 2012 | $0.36 | Quarterly |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ2024 Financhle. All Rights Reserved.